Topic

Articles

Decentralized tools and technologies will continue to provide new opportunities for patient engagement post-COVID.

Refining, Rethinking, and Decentralizing Clinical Research

Jill Wechsler is Pharm Exec's Washington Corespondent

R&D on medical treatments lags notable success with vaccines.

Where Are the Therapeutics to Combat COVID-19?

Jill Wechsler reports on FDA's newly published strategies supporting broader eligibility criteria for Phase III studies.

Diversity in Clinical Trials Gains Ground during Pandemic

Utilizing natural language processing technologies to improve search capabilities and advance the development of therapies.

Accelerating Rare Disease Drug Development with NLP: Three Use Cases

Laura Child is CRO Sector Lead at ramarketing

Oral solid dose formulations (OSD) continue to lead the market as a preferred dosage form. To gain better insight into drug dose delivery technology trends, Laura Child spoke to leaders from five top contract development and manufacturing organizations to find out what is on the horizon for patient-centric drug delivery.

New Horizons for Patient-Centric Drug Delivery

Hannah Brown & Elizabeth Baynton, Ipsos Global Autoimmune Therapy Monitors.

Hannah Brown & Elizabeth Baynton explore the atopic dermatitis patient-doctor dynamic and identify opportunities to optimize patient outcomes.

Challenges of Patient Engagement in Atopic Dermatitis

Julian Upton is Pharmaceutical Executive’s European and Online Editor. He can be reached at 

With pharma increasingly exploring the therapeutic potential of psychedelic drugs, Pharm Exec looks at how three companies in this space are developing their pipelines.








Tuning (Back) into Psychedelics

Elaine Quilici is Pharmaceutical Executive's Senior Editor. Email her at equilici@mmh.com

Michael Henderson, Chief Business Officer, BridgeBio spoke to Pharm Exec about his efforts in developing potential treatments for rare diseases.

Looking to Past Research for the Development of New Drugs

Anthony Finbow, CEO of Eagle Genomics, talks to Pharm Exec about how adding microbiome-based evidence to disease modeling will enable the life sciences industry to understand the subtleties of how drugs interact with different human ‘host’ environments, unlocking new potential for stratified treatments. 

 Tapping Microbiome Science for New Treatments and Answers to Drug Efficacy

's Online and European Editor. He can be reached at jupton@mjhlifesciences.com

Dr. Husseini Manji talks to Pharm Exec about his new role as J&J's Head of Science for Minds and how he hopes to foster new ways to treat dementia and serious mental disorders and provide holistic mental care.

R&D/Clinical Trials